Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Ally Financial
ALLY
5
Bank of America
BAC
AU Stock MarketDetailed Quotes
PXS Pharmaxis Ltd
- 0.027
- 0.0000.00%
20min DelayMarket Closed Apr 11 10:00 AET
19.51MMarket Cap-1.59P/E (Static)
0.000High0.000Low0Volume0.000Open0.027Pre Close0.00Turnover0.03052wk High0.00%Turnover Ratio722.61MShares0.02652wk Low-0.017EPS TTM8.93MFloat Cap0.150Historical HighLossP/E (Static)330.70MShs Float0.026Historical Low-0.017EPS LYR0.00%Amplitude--Dividend TTM2.08P/B1Lot Size--Div YieldTTM
Pharmaxis Ltd News
Pharmaxis Ltd Highlights Uncertainties in Syntara's Future Projections
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Pharmaxis Ltd Announces Substantial Shareholding Disclosure
Canaccord Genuity Sticks to Their Buy Rating for Pharmaxis Ltd (SNT)
Pharmaxis Ltd Reveals Interim Results at Hematology Forum
Pharmaxis Ltd Director Increases Stock Options
Pharmaxis Ltd: A Powerhouse of Pharmaceutical Expertise
Pharmaxis Ltd Calls for Key Shareholder Vote
Pharmaxis Advances Cancer Drug in German Trials
Pharmaxis Shareholding Shifts With Platinum Moves
Pharmaxis Ltd Announces Upcoming Equity Raise
Pharmaxis Ltd's Aspirations Amidst Uncertainties
Pharmaxis Ltd Advances Clinical Trials, Boosts Savings
Pharmaxis Ltd Announces Major Shareholder Changes
Syntara Receives AU$5.2 Million R&D Tax Rebate
Pharmaxis Doses First Patient in Phase Two Sleep Trial
Pharmaxis Sells Mannitol Business; Shares Fall 3%
Pharmaxis Target Price Raised 31% to A$0.17/Share by Morgans>PXS.AU
Pharmaxis to Change Name Amid Restructure, Appoints Chair
Pharmaxis to Be Renamed Syntara and Will Primarily Focus on Clinical Development
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
Warren Buffett's Q1 Holdings Revealed: Has the Investment Trend Changed Drastically?
$Berkshire Hathaway-A (BRK.A.US)$ The first quarter Hold Positions report has been released, and the latest investment actions of the 'stock
Moomoo News Global
May 4 18:27
10 Unmissable Highlights of Berkshire's Shareholders Meeting